LAKE FOREST LABORATORY

START FAST IN CALIFORNIA. SCALE GLOBALLY WITH CELLCARTA.

CellCarta

Early-stage programs can't afford delays or uncertain results. Pipelines are intensifying, biological complexity is growing, especially in multi-component therapies like ADCs, and the need for high-quality, reliable results is higher than ever.

Our Lake Forest laboratory delivers speed, flexibility, and scientific partnership, backed by our fully-owned global laboratories.

WHY TEAMS CHOOSE OUR CALIFORNIA SITE

- **Speed Without Compromising Quality**
  Pathologist-validated data delivered on early-stage timelines, with the rigor required to support critical program decisions.
- **Flexibility for Programs That Evolve**
  Protocols, scope, and timelines adapt as your program expands, pivots, or accelerates.
- **Direct Scientific Partnership**
  Work as one team with our scientists and pathologists, with real-time updates and meaningful dialogue.
- **Confidence in Your Data**
  Scientific rigor and quality control processes are at the center of every project, delivering high-quality, reliable results from day one.
- **In-House Biobank Access**
  Immediate specimen availability eliminates sourcing delays and accelerates project initiation.
- **Built for Global Expansion**
  Start locally at our 21,400 sq. ft. Lake Forest facility, and scale seamlessly across CellCarta's owned global network with proven cross-site assay harmonization.

BY NUMBERS

20/20
TOP PHARMA COMPANIES TRUST US

25+yr
SUPPORTING PHASE 1, 2 & 3 STUDIES

<3mo
CONCEPT TO VALIDATED ASSAY

600+
READY TO DEPLOY ASSAYS

1,500+
ASSAY DEVELOPMENT STUDIES

2,400+
UNIQUE PROJECTS COMPLETED

SPECIALIZED IN ADC BIOMARKER PROFILING

Advanced multiplexing (up to 40 markers) with 270+ digital image analysis algorithms. De novo assay development and validation.

ASSAY LIBRARY

400+
VALIDATED CLINICAL & TRANSLATIONAL

200+
OPTIMIZED EXPLORATORY

BIOBANK

20,000+
TUMOR BLOCKS

2,800+
NORMAL TISSUE BLOCKS

FROM EARLY RESEARCH THROUGH CDx DEVELOPMENT

- De novo assay development & validation
- Spatial & multiplex profiling
- Digital pathology
- Regulatory-grade QC/QA
- CDx development
- Global program scale-up

"CellCarta was one of very few CROs able to deliver the full scope of biomarker work we required under one roof. For a small team, that integrated capability makes our lives a lot easier."

Senior Director, Translational Medicine
ADC Biotech Company

CASE STUDIES

HOW LAKE FOREST DELIVERS UNDER PRESSURE

9 ASSAYS, 1050 SLIDES, 4 WEEKS: RAPID DISCOVERY STUDY FOR A BIOPHARMA TEAM

Prevalence discovery study in endometrial cancer: H&E evaluation and full IHC panel across 70 FFPE blocks.

CHALLENGE

- 70 FFPE blocks: 15 slides per block (1,050 total) across 9 assays
- Hard 4-week deadline from sample receipt to final data delivery

APPROACH

- Parallelized workflows across pathology, digital pathology, and lab ops
- Managed third-party vendors to enable additional testing concurrently

OUTCOME

- All sectioning, staining, and evaluation completed within 4 weeks
- Data and images delivered ahead of sponsor's deadline
- Prevalence data ready for leadership review and program decision-making

CLINICAL DATA DELIVERY IN 6 WEEKS: CUSTOM MULTIPLEX PROGRAM FOR BIOTECH

Two custom 6-plex mIF assays on the Akoya platform for rheumatoid arthritis, with clinical testing of 101 FFPE samples.

CHALLENGE

- Novel multiplex panels requiring complex digital image analysis algorithm development
- Clinical sample testing had to proceed concurrently with assay validation

APPROACH

- Samples pre-staged so clinical testing could begin the moment validation was approved
- Custom H&E evaluation forms developed to standardize assessment across stages

OUTCOME

- mIF clinical testing of 101 samples completed in 6 weeks
- All multiplex data reported ahead of conference deadline
- Results delivered in presentation-ready formats

PRESERVING A CRITICAL SPATIAL BIOLOGY PILOT FOR A LEADING PHARMA

8-plex mIF panel on the Lunaphore COMET platform with HALO AI HighPlex FL digital pathology workflows.

CHALLENGE

- Mid-study discovery that procured samples were collected under IRB-waived consent, making them ineligible
- Assay development and algorithm optimization were already underway

APPROACH

- Replacement tissue samples rapidly sourced through a preferred vendor within one week
- Newly sourced materials introduced without interrupting workflow progress

OUTCOME

- Pilot study preserved with zero interruptions
- HALO AI workflows maintained continuity – no restart required
- Study stayed on track with planned development timelines

CellCarta

Ready to start developing your assay? Connect directly with our Lake Forest team.

www.cellcarta.com | info@cellcarta.com